Background: Recent interest has focused on a unique subgroup of overweight and obese
individuals who have normal metabolic features despite increased adiposity. Normal-weight …

Moderate aLimited use in the US/Europe. bNot licensed in the US cPrescribing highly
restricted in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a …

Importance Numerous glucose-lowering drugs are used to treat type 2 diabetes. Objective
To estimate the relative efficacy and safety associated with glucose-lowering drugs including …

Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major
worldwide health crisis. Modest weight-loss (≥ 5% but< 10%) can minimize and reduce …

Glycaemic management in type 2 diabetes mellitus has become increasingly complex and,
to some extent, controversial, with a widening array of pharmacological agents now …

OBJECTIVE To evaluate the efficacy and safety of canagliflozin, a sodium glucose
cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes …

Introduction: Postprandial hyperglycemia (PPHG) contributes to micro-and macro-vascular
complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due …

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …

Aims Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the
treatment of type 2 diabetes mellitus (T2 DM). This randomised, double‐blind, placebo …

This systematic review with meta-analysis of randomized controlled trials (RCT) aimed to
analyze the effect of fiber intake on glycemic control in patients with type 2 diabetes …